 This study used UPLCQ or Batrap HMS to analyze the chemical components of astragaliratics, AR, and identified 77 AR components absorbed in blood. Network module analysis and molecular docking-based approach were conducted to explore the underlying mechanisms of AR on non-small cell lung cancer, NSC-LC. The study found that TP53, SRC, EP300, and RILA were potential pharmacological targets for AR in treating NSC-LC. The results also showed that RILA was associated with poor prognosis of NSC-LC patients. This article was authored by Wenxiao, Yoshinshu, Jan P. Bach, and others.